Back to top
more

HCA Healthcare (HCA)

(Delayed Data from NYSE)

$415.54 USD

415.54
1,080,848

+9.06 (2.23%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $415.66 +0.12 (0.03%) 6:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 5% (13 out of 250)

Industry: Medical - Hospital

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Integer Holdings (ITGR) Loses 1.3% Despite Q1 Earnings Beat

by Zacks Equity Research

Integer Holdings' (ITGR) first-quarter results reflect weak segmental performance.

Orthofix's (OFIX) Q1 Earnings Top Estimates, 2021 View Up

by Zacks Equity Research

Strong sales of Orthofix's (OFIX) M6-C artificial disc and FITBONE lengthening nail drive its Q1 top line.

Hill-Rom (HRC) Q2 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Hill-Rom's (HRC) second-quarter revenues improved year over year on continued recovery across all three business segments as well as expanded demand for critical care products.

Zacks.com featured highlights include: HCA Healthcare, Landstar System, East West Bancorp and Deere

by Zacks Equity Research

Zacks.com featured highlights include: HCA Healthcare, Landstar System, East West Bancorp and Deere

Acadia Healthcare (ACHC) Q1 Earnings Top Estimates, Rise Y/Y

by Zacks Equity Research

Acadia Healthcare (ACHC) Q1 earnings benefit from revenue gains, led by higher revenue per patient day and an increase in patient days, partly offset by a rise in expenses.

Ensign Group's (ENSG) Q1 Earnings Beat, 2021 EPS View Up

by Zacks Equity Research

Ensign Group's (ENSG) first-quarter results reflect better revenues and a solid performance of its Transitional and Skilled Services.

4 GARP Stocks to Scoop Up for Maximum Returns

by Zacks Equity Research

If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

ResMed (RMD) Q3 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Lower device sales including weak demand for ventilators due to COVID-19 hurt ResMed's (RMD) Q3 top line.

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Guidance Up

by Zacks Equity Research

Bio-Rad's (BIO) first-quarter revenues improved year over year on robust growth in Life Science and Clinical Diagnostics segments.

What's in Store for Fulgent Genetics' (FLGT) Q1 Earnings?

by Zacks Equity Research

COVID-19 testing and NGS-based testing solutions are expected to have contributed to Fulgent Genetics' (FLGT) Q1 earnings.

Looking for Medical Stocks? The Zacks Rank Can Help You Find Winners

by Zacks Equity Research

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.

Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up

by Zacks Equity Research

Syneos Health (SYNH) registers sales uptick in its Clinical Solutions business on the back of favorable acquisition impacts and increased project start-up activities.

Here's How Much You'd Have If You Invested $1000 in HCA Holdings a Decade Ago

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Community Health (CYH) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

Community Health's (CYH) first-quarter results reflect decline in operating and interest expenses, partly offset by weaker admissions.

Humana's (HUM) Q1 Earnings Surpass Estimates, Improve Y/Y

by Zacks Equity Research

Humana's (HUM) Q1 earnings gain from better revenues and a solid contribution by its Retail segment.

Encompass Health (EHC) Q1 Earnings Beat, Hikes '21 View

by Zacks Equity Research

Encompass Health's (EHC) first-quarter results reflect improved Inpatient Rehabilitation segment revenues, partly offset by lower volumes in both its segments and higher costs.

Centene (CNC) Q1 Earnings Miss Estimates, Hikes '21 View

by Zacks Equity Research

Centene's (CNC) first-quarter results reflect higher revenues and growing Medicare as well as Medicaid membership, partly offset by escalating costs.

Universal Health (UHS) Q1 Earnings Top, Revenues Improve Y/Y

by Zacks Equity Research

Universal Health's (UHS) first-quarter results highlight uptick in revenues across both the company's segments, partly offset by escalating costs.

Penumbra (PEN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Growth across vascular thrombectomy and embolization products is expected to have contributed to Penumbra's (PEN) Q1 performance.

What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?

by Zacks Equity Research

IDEXX (IDXX) first-quarter top line is expected to have benefited from strength in CAG and LPD businesses.

Avantor, Inc. (AVTR) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Avantor, Inc. (AVTR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

BioRad (BIO) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Growing demand for Polymerase Chain Reaction and Droplet Digital PCR products is expected to have contributed to BioRad's (BIO) Q1 growth.

Company News for Apr 23, 2021

by Zacks Equity Research

Companies In The News Are: T, HCA, CLF, TSCO

ResMed (RMD) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Improvement in demand for Mask and Other accessories along with rapid adoption of digital health solution is likely to have contributed to ResMed's (RMD) Q3 growth.

LabCorp (LH) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

With respect to LabCorp's (LH) COVID-19 testing services wing, although extensive vaccine rollouts are ongoing, the resurgence of the virus might have once again boosted testing demand in Q1.